Study to Evaluate Safety and Immunogenicity of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children

NCT01003418 PHASE2 TERMINATED Results posted

The purpose of this study is to assess the safety and immunogenicity of two doses of the H1N1 candidate vaccine administered in children aged between 8 and 12 weeks at the time of first vaccination.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE2
Status	TERMINATED
Enrolment	8
Start date	Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Nov 25 2010 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Influenza

Interventions

• GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine
• Infanrix™-IPV/Hib
• Prevenar

Countries

Norway